These observations highlight the relevance of metabolic assessment in the clinical management of herpes zoster and point to the need for future studies integrating comprehensive inflammatory and metabolic biomarkers (e.g., IL-6, TNF-α, adipokines, TyG index, insulin resistance) to clarify the immunometabolic pathways involved in disease severity. This evidence concerns the gene IL6 and herpes zoster.